Darunavir/ritonavir monotherapy in clinical practice

被引：1
|
作者：
Parienti, Jean-Jacques [1 ,2 ,3 ]
机构：
[1] Caen Cote de Nacre Univ Hosp, Dept Infect Dis & Clin Res & Biostat, Caen, France
[2] Univ Paris 06, Paris, France
[3] INSERM, UMR S 707, Paris, France
来源：
AIDS | 2011年 / 25卷 / 01期
关键词：
INDINAVIR;
D O I：
10.1097/QAD.0b013e3283405d2c
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [21] Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients
    Gutierrez-Valencia, Alicia
    Torres-Cornejo, Almudena
    BenMarzouk-Hidalgo, Omar J.
    Ruiz-Valderas, Rosa
    Lluch, Amparo
    Viciana, Pompeyo
    Lopez-Cortes, Luis F.
    ANTIVIRAL THERAPY, 2014, 19 (05) : 443 - 447
  • [22] Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction
    Fabbiani, Massimiliano
    Di Giambenedetto, Simona
    Ragazzoni, Enzo
    D'Ettorre, Gabriella
    Parruti, Giustino
    Prosperi, Mattia
    Bracciale, Laura
    Cauda, Roberto
    Navarra, Pierluigi
    De Luca, Andrea
    PHARMACOLOGICAL RESEARCH, 2011, 63 (03) : 249 - 253
  • [23] Favourable effects on vitamin D and bone of switching from Atripla to darunavir/ritonavir monotherapy
    Hamzah, L.
    Mant, C.
    Cason, J.
    Tiraboschi, J.
    Toby, M.
    Iveson, H.
    Jendrulek, I.
    Kulasegaram, R.
    Teague, A.
    Fox, J.
    Post, F.
    Dew, T.
    Wandolo, E.
    Burling, K.
    HIV MEDICINE, 2015, 16 : 34 - 34
  • [24] CSF inflammatory markers after adding maraviroc to MONotherapy darunavir/ritonavir: the CINAMMON Study
    Barber, T.
    Boffito, M.
    Pozniak, A.
    Davies, N.
    Mandalia, S.
    Gazzard, B.
    Niubo, J.
    Fortuny, R.
    Podzamczer, D.
    Imaz Vacas, A.
    HIV MEDICINE, 2017, 18 : 36 - 36
  • [25] Darunavir/cobicistat as antiretroviral treatment simplification strategy in patients with stable monotherapy with ritonavir-boosted protease inhibitors in the clinical setting
    Ramon Santos, Jose
    Pelaez Ibanez, Pablo
    Bravo, Isabel
    Maria Llibre, Josep
    Paredes, Roger
    Clotet, Bonaventura
    Molto, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [26] Effectiveness of monotherapy with a ritonavir-boosted protease inhibitor for HIV patients in clinical practice
    Moron Romero, Rocio
    Valle, Margarita
    Rodriguez, Alejandro
    Nieto, Pelayo
    Casas, Inmaculada
    Cabeza, Jose
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 330 - 330
  • [27] Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
    Gisslen, Magnus
    Fuchs, Dietmar
    Hagberg, Lars
    Svennerholm, Bo
    Zetterberg, Henrik
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 44 (12) : 997 - 1000
  • [28] Budget Impact Analysis of Switching to Darunavir/Ritonavir Monotherapy for HIV-Infected People in Spain
    Pasquau, Juan
    Gostkorzewicz, Joana
    Ledesma, Francisco
    Anceau, Anne
    Hill, Andrew
    Moecklinghoff, Christiane
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2012, 10 (02) : 139 - 141
  • [29] Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial
    Arribas, J.
    Pulido, F.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 164 - 164
  • [30] Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial
    Arribas, Jose
    Pulido, Federico
    Hill, Andrew
    van Delft, Yvon
    Moecklinghoff, Christiane
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (08) : 679 - 681
12345